MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

InflaRx NV

Gesloten

1.12 10.89

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1

Max

1.15

Belangrijke statistieken

By Trading Economics

Inkomsten

12M

-5.1M

Verkoop

-124K

-423

EPS

-0.08

Winstmarge

1,208,456.738

Werknemers

74

EBITDA

12M

-5M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+630.48% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-11M

70M

Vorige openingsprijs

-9.77

Vorige sluitingsprijs

1.12

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

InflaRx NV Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 apr 2025, 23:55 UTC

Populaire aandelen

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 apr 2025, 22:50 UTC

Belangrijke Marktbewegers

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 apr 2025, 21:08 UTC

Winsten

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 apr 2025, 21:00 UTC

Winsten

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 apr 2025, 23:56 UTC

Marktinformatie

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 apr 2025, 23:44 UTC

Marktinformatie

Global Equities Roundup: Market Talk

2 apr 2025, 23:44 UTC

Marktinformatie

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 apr 2025, 23:44 UTC

Top Nieuws

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 apr 2025, 23:32 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 23:32 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

2 apr 2025, 23:32 UTC

Marktinformatie

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 apr 2025, 23:12 UTC

Marktinformatie

Global Equities Roundup: Market Talk

2 apr 2025, 23:12 UTC

Marktinformatie

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 apr 2025, 23:10 UTC

Marktinformatie

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 apr 2025, 23:09 UTC

Marktinformatie

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 apr 2025, 23:09 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 22:57 UTC

Marktinformatie

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 apr 2025, 22:56 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 22:56 UTC

Marktinformatie

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 apr 2025, 22:43 UTC

Top Nieuws
Acquisities, Fusies, Overnames

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 apr 2025, 22:12 UTC

Marktinformatie

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 apr 2025, 21:48 UTC

Top Nieuws

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 apr 2025, 21:41 UTC

Marktinformatie

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 apr 2025, 21:17 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 21:17 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

2 apr 2025, 21:17 UTC

Marktinformatie

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 apr 2025, 21:04 UTC

Top Nieuws

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 apr 2025, 21:03 UTC

Marktinformatie

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 apr 2025, 20:53 UTC

Winsten

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 apr 2025, 20:52 UTC

Winsten

Kaiser Aluminum Changes Inventory Acctg Methodology

Peer Vergelijking

Prijswijziging

InflaRx NV Prognose

Koersdoel

By TipRanks

630.48% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 7.67 USD  630.48%

Hoogste 10 USD

Laagste 5 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor InflaRx NV - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

3

Buy

1

Hold

0

Sell

Technische score

By Trading Central

1.02 / 1.24Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Very Strong Bearish Evidence

Lange Termijn

Strong Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over InflaRx NV

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.